COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial

Main Article Content

Andrew Blauvelt
Andrew Pink
Margitta Worm
Richard Langley
Antonio Costanzo
Le Gjerum
Emilie Jorgensen
Joshua Corriveau
Emma Guttman-Yassky

Keywords

tralokinumab, COVID-19, ECZTEND trial, atopic dermatitis

Abstract

N/A

References

1. Weidinger S, Novak N. Lancet. 2016;387:1109–22;

2. Eckert L, et al. J Am Acad Dermatol. 2017;77:274–9.e273;

3. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121:340–7;

4. Dalgard FJ, et al. J Invest Dermatol. 2015;135:984–91;

5. Bieber T. Allergy. 2020;75:54–62;

6. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480–9;

7. Popovic B, et al. J Mol Biol. 2017;429:208–19;

8. Wollenberg A, et al. Br J Dermatol. 2020. doi:10.1111/bjd.19574;

9. Silverberg JI, et al. Br J Dermatol. 2020. doi:10.1111/bjd.19573;

10. Merola J, et al. Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderateto-severe atopic dermatitis. J Am Acad Dermatol. 2021. Published online 17 March 2021. Doi: 10.1016/j.jaad.2021.03.032

Most read articles by the same author(s)

<< < 1 2 3 4 5 > >>